Scientific Article on the Impact of Anti-Malarial Drug on COVID Treatment Withdrawn

A scientific study examining the effectiveness of the drug hydroxychloroquine in treating COVID-19 has been officially retracted by the international journal "Antimicrobial Agents" after years of debate and controversy in scientific circles. This study, which was initially presented as one of the hopeful treatments against the coronavirus, is now facing serious criticisms regarding its methodology and results. Didier Raoult, a French physician and one of the main authors of this article, is now facing legal and professional issues. He has been banned from practice by the French Medical Council due to his controversial approach to COVID-19 treatment, and multiple lawsuits have been filed against him. The publisher, Elsevier, which also publishes the journal "Antimicrobial Agents," announced concerns about the article's adherence to "ethical policies and appropriate research conduct with human participants." The publication also stated that further research conducted by independent advisors revealed serious flaws in this study, particularly regarding methodology and data analysis, including whether all patients received the experimental drugs knowingly and with their consent. Part of the retraction note published by the journal states that it cannot confirm a correct and complete reflection of the collected data in the article. The journal also announced that three authors of the article, out of a total of 18 authors, had previously requested to have their names removed due to objections to how the results were presented and interpreted. Additionally, the public prosecutor's office in Marseille has begun investigations into the quality of research and care activities conducted at the institute led by Didier Raoult. Hydroxychloroquine is a drug primarily used for the treatment and prevention of a specific type of malaria. Dr. Raoult, a microbiologist and professor at Aix-Marseille University in France, attracted international attention during the COVID-19 pandemic by claiming that hydroxychloroquine could be used as a treatment for the coronavirus. The U.S. Food and Drug Administration issued an emergency authorization for the use of hydroxychloroquine in March 2020 but revoked it in June 2020 due to a lack of evidence supporting the drug's effectiveness. Studies have also shown that the use of this drug is associated with multiple immune and cardiac problems.